Prevalence of linezolid resistance in Streptococcus pneumoniae isolates: a systematic review and meta-analysis

Abstract

Aim: This study aimed to understand the current level of linezolid (LNZ) resistance in Streptococcus pneumoniae isolates reported over the past 10 years. Material & methods: An electronic search was conducted for the following keywords: ((Streptococcus pneumoniae [title/abstract]) OR (Pneumococcus [title/abstract]) OR (Pneumococci [title/abstract]) AND (linezolid [title/abstract]) OR (Zyvox [title/abstract])) OR (Zyvoxid [title/abstract])). Result: Out of all the studies, 80 had a cross-sectional design, while 11 followed a cohort approach. The prevalence of LNZ resistance among S. pneumoniae isolates ranged from 0% to 4.86%. Discussion: Urgent, high-powered, randomized, controlled trials with participants from endemic regions are needed to gain a comprehensive understanding of the impact on and significance of LNZ treatment to patients.

Keywords: :

• community-acquired pneumonia
• linezolid
• resistant
• Streptococcus pneumoniae
• treatment

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/fmb-2023-0170

Author contributions

M Heidari and R Ghanavati conceived, designed and supervised the study. S Dashtbin and R Ghanavati contributed to data collection, interpretation and final approval of data for the work. A Asadi and R Pakzad developed the first and final drafts of the manuscript. A Khatib, P Asadollahi, MM Ebrahimi, and Z Ghanbari developed the second draft of the manuscript. All figures and tables were designed and checked by A Darbandi and M Heidari. All authors reviewed and contributed to the revisions and finalized the drafts.

Financial disclosure

This study was supported by a grant from Behbahan Faculty of Medical Sciences (grant number 401126). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

This study received approval from the Ethics Committee (code number: IR BUN.REC.1402.049) of Behbahan Faculty of Medical Sciences.